Abstract
Image-guided stereotactic ablative radiotherapy (SABR, also known as stereotactic body radiotherapy) is a non-invasive treatment by delivering ablative doses of radiation over one to ten fractions to tumors, and it achieves local control in excess of 90%. SABR has become a standard treatment for medically inoperable and an option for operable clinical early-stage non-small-cell lung cancer (NSCLC). The university of Texas MD Anderson Cancer Center (MDACC), as a top institute of cancer research and treatment worldwide, has conducted a series of influential SABR clinical trials and researches. The results have greatly promoted the application of SABR in early- and advanced-stage NSCLC. Here we summarize the clinical application, study progresses and findings of SABR for NSCLC in MDACC. Key words: Stereotactic body radiotherapy (SBRT); Stereotactic ablative radiotherapy (SABR); Non-small-cell lung cancer (NSCLC); MD Anderson Cancer Center
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
